Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.

Abstract: Described herein is the evaluation of the antifungal properties of bacterial strain KGS-3 against Fusarium Head Blight (FHB)) white mold, blackleg and a number of potato fungal diseases and the plant growth effect attained. KGS-3 is a novel strain of Paenibacillus polymyxa that can suppress bacterial and fungal plant diseases. KGS-3 is predicted to produce antifungal metabolites polymyxin, fusaricidin, and paenilarvin and has been demonstrated to produce cylindrol B. KGS-3 is a plant growth promoting bacteria demonstrated to increase protein content of plants and/or plant products.

Abstract: The present invention relates to polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides of the invention to release xylose and in animal feed.

Abstract: The present disclosure relates to the seminal discovery of a generation and use of genetically engineered Vibrio sp. Provided is the use of the genetically engineered bacteria for the construction, maintenance, manipulation, and/or propagation of DNA constructs; protein expression; protein secretion; vectors and other metabolic tools; metabolic engineering; expression of cellular extracts for cell-free biology; shuttle vectors; cloning vectors; and for synthetic biology applications. The disclosure also relates to the use of the replication machinery of Vibrio sp. as a cloning or expression vector for replication of recombinant DNA constructs. The disclosure also relates to methods of use of the above.

Abstract: Lactobacilus reuteri CH53 strain has high productivity of 1,3-propanediol from glycerol and uses thereof. It is confirmed that Lactobacilus reuteri CH53 strain is capable of converting at very high yield glycerol or crude glycerol to high-concentration 1,3-propanediol. Since Lactobacilus reuteri CH53 strain of the present invention capable of producing large amounts of 1,3-propanediol is one kind of lactic acid bacteria that are safe for humans (GRAS, Generally Recognized As Safe), when it is used for producing 1,3-propanediol from crude glycerol, it would be very advantageously used, unlike existing GMO strains, in related industries from the viewpoint of safety or environment and also providing an advantage of recycled use of resources.

Abstract: Methods of producing fatty acid esters, such as fatty acid ethyl esters, from genetically engineered microorganisms are described.

Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

Abstract: The present invention refers to lambda integrases comprising at least one amino acid mutation at positions 43, 319 and 336 of the lambda integrase as set forth in SEQ ID NO: 1. The invention further refers to nucleic acid molecules comprising the nucleotide sequence encoding the mutant lambda integrase and to host cells containing these nucleic acid molecules. The invention also refers to methods of recombining a nucleic acid of interest into a target nucleic acid in the presence of the mutant lambda integrase and sequence specific recombination kits.

Abstract: The present invention relates to a mutant fungal strain of Penicillium funiculosum ‘MRJ-16’ characterized by the ability to produce high titer of enzyme mixture comprising FPase, CMCase, Cellobiase, ?-glucosidase, endoglucanase, ?-L arabinofuranosidase, ?-xylosidase, xylanase, pectinase, cellobiohydrase and oxidases and produce enzymes in the presence of a catabolite repressor molecule like glucose and/or xylose. The titer of enzyme mixture produced using mutant fungal strain MRJ-16 is at least two fold higher than naive Penicillium funiculosum strain NCIM 1228, when used in a fermentation process. The mutant strain ‘MRJ-16’ with high hydrolytic activity and catabolite derepressed character is having application in the method of degrading or saccharifying biomass to produce valuable products for example-bioethanol.

Abstract: The present disclosure relates to a composition for producing tagatose comprising a protein having fructose-4-epimerase activity and a method for producing tagatose using the same.

Abstract: Provided are a composition for producing tagatose, comprising fructose-4-epimerase, and a method of producing tagatose using the same.

Abstract: This invention provides polypeptides that were identified as interacting with Vip3 toxin. This invention also provides a method of identifying agents that bind to Vip3 interacting polypeptides, which agents may act as insecticidal agent, cytotoxic agents and/or modulate the activity of Vip3 interacting polypeptides.

Abstract: The present disclosure discloses a genetically engineered strain, belonging to the technical field of bioengineering. L-amino acid oxidase genes, ?-keto acid decarboxylase genes, alcohol dehydrogenase genes, and enzyme genes capable of reducing NAD(P) to NAD(P)H are introduced into the genetically engineered strain of the present disclosure. The present disclosure further discloses a construction method and application of a recombinant Escherichia coli genetically engineered strain. When being applied to the biosynthesis of phenylethanoids, the method of the present disclosure has the characteristics of simple operation, low cost, and high synthesis efficiency and optical purity of the product, and has good industrialization prospects.

Abstract: The present disclosure relates to methods of using transaminase polypeptides in the synthesis of chiral amines from prochiral ketones.

Abstract: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

Abstract: Described are compositions comprising ?-galactosidase A enzymes with unique carbohydrate profiles, as well as methods for manufacturing and purifying such enzymes. Also described methods of treating, preventing, and/or ameliorating Fabry Disease by administering such enzymes to a subject in need thereof. Also described are compositions comprising migalastat in combination with such ?-galactosidase A enzymes.

Abstract: An isolated nucleic acid encoding a leader, which has a specific sequence, an isolated leader peptide encoded by such nucleic acid, an expression cassette comprising such nucleic acid encoding a leader operably linked to a nucleic acid sequence encoding a POI a recombinant yeast host cell or a vector comprising such expression cassette, a method of producing a POI in such yeast host cell, and further the use of the specific nucleic acid for the secretion of a POT from a host cell and/or to increase the secretion of a POT from a host cell.

Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: Direct detection of mutagenesis in prokaryotes by reversion of an inactivating mutation (reversion mutation assay), producing a quantitative signal for in vivo mutagenesis, may greatly reduce the amount of test chemicals and labor involved in these assays. Further, transcriptional coupling of ?-lactamase reversion and GFP, translational fusion between ?-lactamase and GFP with stop codon in GFP, and a novel dual reporter to monitor continuous mutagenesis may be used in methods described herein.

Abstract: The present invention relates to a novel variant RNA polymerase sigma factor 70 (?70) polypeptide, a polynucleotide encoding the same, a microorganism containing the polypeptide, and a method for producing L-threonine by using the microorganism.